Source study found
Story checked
Radiotherapy after surgery significantly reduces atypical meningioma recurrence, clinical trial finds (opens in a new tab)
medicalxpress.com · 2026-09-25
Short answer
Needs reviewStudy found.
We found the study, but the claim check did not finish.
Checked against the study summary. The full text wasn't available, so some details couldn't be settled either way.
Share this check
The story
Radiotherapy after surgery significantly reduces atypical meningioma recurrence, clinical trial finds
medicalxpress.com · 2026-09-25
The story’s checkable claims.
Read the original story (opens in a new tab)NewsLink checks it
We found the study behind this story.
We found the study, but couldn't compare the story to it: the study's evidence could not be profiled.
Open claim evidenceThe source study
Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial
Evidence layer
Claim by claim
The source study was found, but the study's evidence could not be profiled, so these claims couldn't be checked.
Reading mode
Scan verdicts. Open evidence only when needed.
Claim 1 of 4Not checkedRadiotherapy after complete surgical removal of an atypical meningioma significantly reduces the risk of recurrence, according to the trial.View evidenceHide evidence
As statedsignificantly reduces
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 2 of 4Not checkedThe study involved 157 patients after complete removal of an atypical meningioma; 78 were randomly assigned to 30 sessions of radiotherapy and 79 were monitored with regular imaging.View evidenceHide evidence
As stated157 patients; 78 vs 79; 30 sessions
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 3 of 4Not checkedAfter a median follow-up of around five years, recurrence occurred in 11 of 78 patients (14%) in the radiotherapy group versus 24 of 79 patients (30%) in the observation group, and five-year recurrence-free survival was 79.9% versus 64.3%.View evidenceHide evidence
As stated11/78 (14%) vs 24/79 (30%); 79.9% vs 64.3%
Not checked
The source study was found, but this claim couldn't be checked against it.
Claim 4 of 4Not checkedThe authors say the trial provides the best available evidence for adjuvant radiotherapy after complete resection of atypical meningioma, but the decision should be made jointly with patients because side effects and long-term consequences matter and serious radiation-related events were rare.View evidenceHide evidence
Not checked
The source study was found, but this claim couldn't be checked against it.
Method layer
NewsLink found the paper. Tessa takes you deeper.
NewsLink checks the story. Tessa is where you inspect the paper, authors, evidence, and research context.
Open the paper in Tessa
Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial
The Lancet · 2026
Why this one
Near certain
NewsLink found the paper. Tessa is where you inspect it deeply.
Papers considered
The selected paper, plus nearby candidates.
Crossref, Europe PMC, PubMed · 39 candidate papers
Radiotherapy versus observation following surgical resection of WHO grade 2 atypical meningioma (ROAM/EORTC-1308): an international, multicentre, open-label, phase 3, randomised controlled trial
The Lancet · 2026 · Crossref
Future of neurosurgery
British Journal of Neurosurgery · 2026 · Crossref
Use of pre-operative blood products in abdominal trauma: a planned secondary analysis of the GOAL-trauma study.
2026 · Europe PMC
Molecular findings of incidental meningioma may shape clinical management
Neuro-Oncology · 2026 · Crossref
Evaluating quality of colorectal cancer surgery across elective and emergency health systems: secondary analysis of prospective cohort studies in 95 countries.
2026 · Europe PMC
general author comment
2026 · Crossref
And 33 more candidates considered.